Register
Study shows significant clinical improvement with ixekizumab in patients with ankylosing spondylitis |
Journal Updates
eMediNexus Coverage from: 
Study shows significant clinical improvement with ixekizumab in patients with ankylosing spondylitis
eMediNexus,  08 November 2018
remove_red_eye 542 Views
#Orthopedics #Pharmacist #Rheumatology

0 Read Comments                

Treatment with 80‐mg subcutaneous ixekizumab every 2 or 4 weeks for 16 weeks in patients with active radiographic axial spondyloarthritis (r‐axSpA) and previous inadequate response or intolerance to 1 or 2 TNF inhibitors (TNFi) yielded rapid and significant improvements in the signs and symptoms of r‐axSpA compared to placebo, as per results from the placebo‐controlled, Phase 3 COAST-W study.

To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!